-
Achieved 22% total revenue growth in Q4 2025, driven by a 31% increase in clinical revenue as the core business reaccelerated toward historic levels.
-
It will process nearly 1 petabyte of genomic data in 2025, doubling the volume from two years ago due to a market shift toward large comprehensive panels and multi-omics analyses.
-
Adjusted gross margin expanded by 140 basis points to 74.2% through a major architectural modernization that increased computing power tenfold and reduced whole-genome analysis time to less than 6 hours.
-
Secured two of the largest integrated health systems in the US, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients.
-
Maintained high platform stickiness with less than 1% annualized revenue loss and a Net Promoter Score of 67, validating the decentralized AI deployment model.
-
It announced a leadership transition with Ross Muken to become CEO in July 2026, while founder Jurgi Camblong moves to executive chairman to focus on technical innovation.
-
Leveraging a diverse data stream from 75 countries to launch ‘digital twins’ for lung cancer, enabling AI-driven virtual simulations for therapy selection.
-
Projecting 2026 revenue between $92 million and $94 million, with growth heavily weighted in the back half as record 2025 reserves transition into routine use.
-
Management anticipates a net positive biopharma contribution in 2026 as its story begins to resonate with C-suite at top 20 pharmaceutical companies, although it is not yet forecasting a dramatic acceleration or “hockey stick” growth for that year.
-
Target adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 by reducing 60% of incremental revenue to the bottom line.
-
Assuming continued expansion of ASP as customers migrate to higher value products such as MSK-ACCESS and Enhanced Exomes, despite lower ASP volume growth in emerging markets.
-
Plan to keep operating expenses stable in local currency by flattening organizational structures and optimizing discretionary spending.
-
It reported significant adverse currency impacts due to a 14% appreciation of the Swiss franc, which inflated payroll and rental expenses in US dollar terms.
-
Incurred $1.8 million in legal expenses related to patent litigation with Guardant Health; However, the Unified Patent Court recently rejected Guardant’s request for provisional measures.
-
Strengthened liquidity by raising $15.5 million through an ATM service and extending a line of credit with Perceptive Advisors by $25 million.
-
Identified record net dollar retention of 115%, up from 104% the prior year, driven by successful cross-selling of additional clinical applications.